Impaired in vivo mitochondrial function but similar intramyocellular lipid content in patients with type 2 diabetes mellitus and BMI-matched control subjectsVera B. Schrauwen‐Hinderling, Patrick Schrauwen|Diabetologia|2006Cited by 304
A randomized placebo-controlled clinical trial for pharmacological activation of BCAA catabolism in patients with type 2 diabetesFroukje Vanweert, Esther Phielix, Michael D. Neinast et al.|Nature Communications|2022Cited by 82
Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 DiabetesMartin Schön, Volker Burkart, Vera B. Schrauwen‐Hinderling et al.|Diabetes|2023Cited by 11
Association of thyroid function with non‐alcoholic fatty liver disease in recent‐onset diabetesNina Saatmann, Martin Schön, Oana‐Patricia Zaharia et al.|Liver International|2023Cited by 8
Die postprandiale GLP-1- und GIP-Sekretion ist bei kürzlich diagnostiziertem Typ-2-Diabetes reduziert, aber bei steatotischer Lebererkrankung erhöhtMaximilian Huttasch, Michael Roden, Toshio Mori et al.|Diabetologie und Stoffwechsel|2025Cited by 0